Allstocks.com's Bulletin Board
Stocks, Over $0.10 GMED
|
UBBFriend: Email This Page to Someone! | next newest topic | next oldest topic |
Author | Topic: GMED |
1BigTip Member |
posted April 12, 2004 14:16
GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. After establishing the superiority of a treatment protocol in clinical trials, the Company charges patients a reasonable license fee to use the protocol, which is patented. This summer the Company is conducting a nationwide free clinical trial for West Nile virus encephalitis which will be published before the 2005 West Nile virus season begins. If the Company's protocol continues to be successful, GenoMed will market it beginning next year. GenoMed is currently marketing its protocol for delaying or even preventing complications of high blood pressure and diabetes, which affect 80 million Americans, as well as emphysema, which affects another 3 million people in the U.S., as well as 60 million smokers. http://www.genomedics.com David W. Moskowitz, MD, MA, FACP of GenoMed Inc., +1-314-977-0115, dwmoskowitz@genomedics.com IP: Logged |
1BigTip Member |
posted April 12, 2004 14:18
Just wanted to start a new thread. This company has much potential! I own it since .054 just 2 months ago! Its now at .17! New PR came out today. A 79-year-old male patient from Scioto County, Ohio who was admitted two weeks ago in a coma due to viral encephalitis. His antibody titers are still pending, but his case so far is consistent with West Nile virus encephalitis. Within 24 hours of starting GenoMed's treatment, the patient could move his fingers and toes when asked to do so. IP: Logged |
FurrySound Member |
posted April 12, 2004 22:02
Yes. I've been following them for over a year now. Lots of great progress. There is lots of information available on them for your DD. IP: Logged |
roger7485 Member |
posted April 13, 2004 02:04
Also look into ADOT for a multi year hold. They own a good deal of GMED and have a stranglehold on a multibillion dollar market. Check it out. IP: Logged |
FurrySound Member |
posted April 13, 2004 09:10
Thanks Roger. Will check them out also. IP: Logged |
1BigTip Member |
posted April 22, 2004 12:18
Hmmm, A SARS outbreak in China was reported today. Could that be why this stock is moving higher? Anyone hold this? IP: Logged |
1BigTip Member |
posted April 22, 2004 15:48
GMED 10k is out! Here are the main points: As of December 31, 2003, we had 125,691,027 shares outstanding. As of December 31, 2003, we had 48,234,831 options outstanding. As of March 18, 2004, we had 187,716,591 shares outstanding. This is where the additional shares went to: On January 8, 2004, we sold 4,703,633 shares of our common stock at $0.0213 per share or an aggregate of $100,000 to Research Capital On January 9, 2004, we sold 11,121,409 shares of our common stock to Advanced Optics Electronics at $0.027 per share or an aggregate of $300,000. On January 23, 2004, we issued 1,000,000 shares of our common stock to Peter Brooks in connection with his exercise of options granted to him. The options were exercised at $0.006 per share or an aggregate of $6,000. On February 5, 2004, we issued 6,679,435 shares of our common stock to Research Capital for debt conversion of $180,657. On February 5, 2004, we issued 100,000 shares of our common stock to Scott Williams in connection with his exercise of options granted to him. The options were exercised at $0.025 per share or an aggregate of $2,500. On February 6, 2004, we sold 11,121,411 shares of our common stock to Advanced Optics Electronics at $0.027 per share or an aggregate of $300,000. On February 9, 2004, we issued 769,231 shares of our common stock to Keith Boyer in connection with his exercise of 769,231 warrants at an exercise price of $0.05 or an aggregate exercise price of $38,461. On March 8, 2004, in connection with our agreement with Pierpoint Investments, we sold 833,333 shares of our common stock to Robin Carr at $0.045 per share or an aggregate of $37,500. On March 10, 2004, we sold 11,121,410 shares of our common stock to Advanced Optics Electronics at $0.027 per share or an aggregate of $300,000. On March 11, 2004, in connection with our agreement with Pierpoint Investments, we sold 411,112 shares of our common stock to N. Shah at $0.045 per share or an aggregate of $18,500. On March 11, 2004, in connection with our agreement with Pierpoint Investments, we sold 411,112 shares of our common stock to A. Desch at $0.045 per share or an aggregate of $18,500. On March 11, 2004, in connection with our agreement with Pierpoint Investments, we sold 204,445 shares of our common stock to L. Fitzpatrick at $0.045 per share or an aggregate of $9,200. On March 12, 2004, we sold 6,012,658 shares of our common stock at $0.0632 per share or an aggregate of $380,000 to Research Capital. On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 200,000 shares of our common stock to L. Fitzpatrick at $0.045 per share or an aggregate of $9,000. On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 200,000 shares of our common stock to I. Patel at $0.045 per share or an aggregate of $9,000. On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 200,000 shares of our common stock to D. Limmer at $0.045 per share or an aggregate of $9,000. On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 200,000 shares of our common stock to Weighill Builders at $0.045 per share or an aggregate of $9,000. On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 111,112 shares of our common stock to R. Shah at $0.045 per share or an aggregate of $5,000. On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 150,000 shares of our common stock to L. Peterman at $0.045 per share or an aggregate of $6,750. On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 150,000 shares of our common stock to M. Paerse at $0.045 per share or an aggregate of $6,750. On March 18, 2004, we issued 6,058,560 shares of common stock to Research Capital for debt conversion of $153,081. During 2003 we targeted the discovery of disease genes associated with Type 2 Diabetes and Colon Cancer, but lacked the funding to do so. During 2004, our next phase of operations, we have decided to focus solely on identifying genes for common cancers, since we believe we can already prevent type 2 diabetes itself and its complications. Cancer-causing genes affect a large population base with ample opportunities for disease-gene related products and services. The first samples to be collected will involve such common cancers as lung, prostate, colon, breast and pancreas. We will accomplish our analysis of individual SNPS, as previously defined under "Our Research and Development Approach", through ultra-high throughput (UHT) machines. Genotyping consists of two phases: screening, wherein a relatively small number of cases and controls are genotyped at a large number of SNPs, and validation, wherein a considerably larger number of cases and controls are genotyped at a small number of SNPs. The Orchid UHT machine we purchased and installed at DNAprint Genomics, for example, will accomplish validation genotyping. To date we have earned only $6,410 of revenues. Currently, a patient can subscribe to our Clinical Outcomes Improvement Program(tm) for $67 a month. We have twelve such agreements. During 2001, we spent $333,264 on our research and development. During 2002 and 2003, we spent no funds on research and development. We have no part-time employees. We have 1 full-time employee, our President/Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Chairman of the Board/Chief Medical Officer, Dr. David Moskowitz, who is responsible for directing our Board of Directors, overseeing all research and development and marketing issues, and supervising all medically-related activities. Additionally, Dr. David Moskowitz is responsible for our overall administration and operation, including finance, marketing, and personnel. Agreement with Pierpoint Investments SA Agreement with E & E Communication Partnership Agreement with PhenoMed, Sdn Bhd Liquidity and Capital Resources During March 2004 the Company agreed to adjust the salary of its president to $183,907 per annum with $48,907 being paid in cash and the balance being paid in common shares of the Company with a 50% discount from the average closing price of the 30 day trading period prior to issuance. During the period from January to April 5, 2004 the Company issued an aggregate of 1,869,231 shares of common stock for cash of $46,962 in addition to the shares described above. The agreements with ADOT, Pierpoint and E&E are attached to the 10K as appendices. [This message has been edited by 1BigTip (edited April 22, 2004).] IP: Logged |
1BigTip Member |
posted April 23, 2004 09:29
GenoMed`s Treatment Showing 100% Response Rate Among Immunocompetent Patients; Nationwide Trial Gaining Momentum April 23, 2004 08:45:00 (ET)
Ten out of ten patients, including 4 over the age of 70, responded completely to GenoMed's treatment. The only failure since late August 2003 when the trial began was a young woman with chronic leukemia treated last September. So far this April, 31 people have downloaded GenoMed's West Nile virus trial document. These include 4 physicians; 3 public health officers, including one from Manitoba, Canada and one from Arizona; 2 people from blood banks and 2 more from hospitals. In addition, 6 patients with chronic residual disease after getting West Nile virus encephalitis last summer have signed up for GenoMed's trial. One patient with right leg paralysis who has been on GenoMed's treatment during the winter has recovered nearly complete function of his right leg. GenoMed's patent-pending protocol uses blood-pressure drugs that are safe and already familiar to most physicians. They're carried in every drug store. The protocol, developed by Dr. David Moskowitz, the Company's Chairman, CEO and Chief Medical Officer, is based on the theory that brain inflammation and death result from an over-response by the patient's immune system to the West Nile virus. GenoMed's protocol gently suppresses the immune system at an early step in its activation. The results of Dr. Moskowitz's first eight patients will be published soon in a peer-reviewed medical journal. If GenoMed's current 100% cure rate for patients who aren't immunosuppressed holds up, GenoMed hopes to prevent all deaths and cases of paralysis from West Nile virus encephalitis in the general population this season. Immunosuppressed patients include those with AIDS, those taking chemotherapy for cancer, and organ transplant recipients. GenoMed's treatment approach is already known not to work for this group, unfortunately. Two other biotechnology companies offer treatments which may benefit immunosuppressed patients. For the general population, GenoMed recommends beginning its treatment protocol once a person develops fever and flu-like symptoms after a mosquito bite, and not waiting for encephalitis to develop. GenoMed hopes to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" button at http://www.genomedics.com . Dr. Moskowitz is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz's research on viruses, including West Nile virus, avian influenza ("bird flu"), and SARS, are regarded as innovative approaches for otherwise incurable diseases. About GenoMed GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. This summer the Company is conducting a nationwide free clinical trial for West Nile virus encephalitis which will be published before the 2005 West Nile virus season begins. If the Company's protocol continues to be successful, GenoMed will market it in 2005. GenoMed is currently marketing its protocol for delaying complications, such as kidney failure, of common diseases like high blood pressure and diabetes, which affect 80 million Americans, and emphysema, which affects another 3 million people in the U.S. IP: Logged |
1BigTip Member |
posted April 27, 2004 19:02
As of April 26, 2004 Outstanding Shares = 161,452,849 Restricted Shares = 57,642,849 Float = 103.8 Million as of 3-4-04 IP: Logged |
1BigTip Member |
posted May 13, 2004 15:45
News out. Charts looking good. 2 non-profit groups which care for wild birds with West Nile virus encephalitis, including American bald eagles, will be using the Company's patent-pending treatment this season.
IP: Logged |
All times are ET (US) | next newest topic | next oldest topic |
© 1997 - 2004 Allstocks.com. All rights reserved.
Powered by Infopop www.infopop.com © 2000
Ultimate Bulletin Board 5.47a